Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flu-M
- Development stage
- Phase 3
- Lead developer
- Saint Petersburg Scientific Research Institute of Vaccines and Serums
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Flu-M** is an egg-derived, seasonal **trivalent inactivated split-virion influenza vaccine** developed by Saint Petersburg Scientific Research Institute of Vaccines and Serums. It contains purified surface and internal antigens from influenza A/H1N1, influenza A/H3N2, and influenza B viruses, formulated to induce protective humoral immune responses against the vaccine-matched seasonal strains. The WHO-prequalified multidose formulation is administered intramuscularly for prophylaxis of seasonal influenza.
- Brand names
- FLU-M
- Other names
- Флю-М
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on Flu-M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flu-M.